Understanding how metabolic stress affects gene regulation in prostate cancer
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer
This study is looking at how stress in the body affects gene activity in prostate cancer, especially how a protein called SRC-2 works with other proteins to help the cancer grow and resist treatment, with the hope of finding new ways to improve care for patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11046548 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which metabolic stress influences gene regulation in prostate cancer, particularly focusing on how certain proteins interact to promote cancer progression. The study aims to understand the role of a specific protein, SRC-2, and its relationship with mitochondrial enzymes in driving cancer metabolism. By examining how these interactions contribute to the development of resistance to standard therapies, the research seeks to uncover new therapeutic targets for advanced prostate cancer. Patients may benefit from insights that could lead to more effective treatments for hormone-resistant forms of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced or metastatic prostate cancer, particularly those who have experienced resistance to androgen deprivation therapy.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients with advanced prostate cancer who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach may yield significant advancements in treatment.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Dasgupta, Subhamoy — Roswell Park Cancer Institute Corp
- Study coordinator: Dasgupta, Subhamoy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.